The pharma business of Strides is led by captive and IP-driven licensing agreements and partnerships across the globe, and significant contractual arrangement with international organizations to treat global pandemics like AIDS, TB and Malaria.
Strides is an innovative provider of oral products, developing and manufacturing orals across therapeutic formats including soft gel capsules in which it is amongst the leading players worldwide, tablets (coated/uncoated), hard gel capsules, powders, granules in sachets, ointments and creams.
Our focus is on niche, difficult to make products which are marketed through a combination of front ended and partnership models. In the UK, we have front ending capabilities through our subsidiary Co-pharma Limited while in the USA, we market our products through partnerships with Alvogen, Perrigo and Pfizer. Our manufacturing facilities are strategically located with liquids and cream manufactured in Milan, Italy and orals and soft gels manufactured in Bangalore, India.
We are one of the largest Indian suppliers of institutionally funded aid projects and an approved supplier to UNICEF, the Clinton Foundation, PEPFAR (the President's Emergency Plan for AIDS Relief), the World Health Organisation, the African Development Bank and other international organisations in the area of global disease management for AIDS, TB and Malaria.
Through our partnership with Sandoz, we supply anti-TB drugs to the Global TB Drug Facility. In addition, Strides is an approved supplier of Oseltamivir (to treat Influenza A or H1N1) to the Ministry of Health, Government of India and has also been prequalified by the World Health Organization for generic Oseltamivir capsules 75mg, making Strides only the second company globally to receive WHO pre-qualification for generic Oseltamivir.